Volume 28, Issue 4 pp. 515-520
ORIGINAL REPORT

Safety of a quadrivalent meningococcal conjugate vaccine in healthy subjects aged 9 months to 55 years in Vietnam

Cong Hung Phan

Cong Hung Phan

Pasteur Institute, Ho Chi Minh City, Vietnam

Search for more papers by this author
Thi Phuong Thuy Nguyen

Thi Phuong Thuy Nguyen

Pasteur Institute, Ho Chi Minh City, Vietnam

Search for more papers by this author
Uyen Y. Doan

Uyen Y. Doan

Pasteur Institute, Ho Chi Minh City, Vietnam

Search for more papers by this author
Thuy An Nguyen

Thuy An Nguyen

Sanofi Pasteur, Ho Chi Minh City, Vietnam

Now working at Hoffman-La Roche, 2 Hai Trieu, Ben Nghe, Quan 1, Ho Chi Minh City, VietnamSearch for more papers by this author
Yaël Thollot

Yaël Thollot

Pasteur Medical Operations, Sanofi Pasteur, Lyon, France

Search for more papers by this author
Maria Carmen Nievera

Corresponding Author

Maria Carmen Nievera

Sanofi Pasteur Asia Pacific, Taguig, Philippines

Correspondence

M. C. Nievera, Sanofi Pasteur Asia Pacific, 21 Flr. One World Place, 32 St. Bonifacio Global City, Taguig 1634, Philippines.

Email: [email protected]

Search for more papers by this author
First published: 05 March 2019
Citations: 1

Abstract

Purpose

Meningococcal disease is a major global health concern due to its severe and sudden clinical manifestations, devastating long-term sequelae, and predominance in younger age groups. This study evaluated the safety of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D; Menactra) in participants aged 9 months to 55 years in Vietnam.

Methods

This was an open-label, single-arm study conducted between June and December 2016. Participants received one 0.5-mL dose of the vaccine, and those aged 9 to 23 months received a second 0.5-mL dose 3 months later. Participants (or their parents or legal guardians) reported adverse events during the 28 days after each dose.

Results

The study included 112 participants aged 9 to 23 months and 112 participants aged 2 to 55 years. Of these 224 participants, 100 (44.6%) had one or more solicited reactions within 7 days following any MenACWY-D dose, mostly injection site pain, lost appetite (in 9 to 23-month-olds), and malaise (in 2 to 55-year-olds). Most solicited reactions were of mild or moderate intensity and resolved within 3 days. Five participants had unsolicited adverse reactions (ARs), two of which (tonsillitis and febrile convulsion), in 9 to 23-month-olds, were considered by the investigator as serious adverse events related to the vaccine. No immediate unsolicited ARs, severe unsolicited nonserious ARs, or unsolicited injection site reactions were reported, and both participants who experienced vaccine-related serious adverse events recovered.

Conclusion

Consistent with studies in other countries, MenACWY-D had an acceptable safety profile in individuals from Vietnam aged 9 months to 55 years (WHO Universal Trial Number: U1111-1143-9207).

CONFLICT OF INTEREST

Yaël Thollot and Maria Carmen Nievera are employees of Sanofi Pasteur. The other authors declare no conflicts of interest. Employees of Sanofi Pasteur participated in conceiving and designing the study, drafting and editing the article, deciding to submit the article for publication, and approving the final, submitted version.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.